What is the 13F Pro Quality Score for KIDS?

13F Pro ranks ORTHOPEDIATRICS CORP (KIDS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KIDS's current score at https://13fpro.ai/research/KIDS (free sign-up required for the full ranking).

Which hedge funds own the most KIDS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of KIDS include BROWN ADVISORY, MILLENNIUM MANAGEMENT, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/KIDS as soon as new 13F filings post.

Where does 13F Pro source KIDS data?

All ORTHOPEDIATRICS CORP fundamentals and ownership data come directly from SEC EDGAR. ORTHOPEDIATRICS CORP files with the SEC under CIK 1425450. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KIDS in?

ORTHOPEDIATRICS CORP (KIDS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KIDS research updated on 13F Pro?

KIDS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ORTHOPEDIATRICS CORP(KIDS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1425450 KIDS stock profile & AI dashboard →

13F Pro Quality Score

33.4/100

Rank #2,232 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

82.7/100

Profitability

16.4/100

Balance Sheet

19.8/100

Earnings Quality

30.0/100

Free Cash Flow

16.9/100

Institutional Flow

32.4/100

Revenue Scale

26.0/100

Dilution Risk

20.5/100

KIDS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ORTHOPEDIATRICS CORP (KIDS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KIDS at 33.4/100 on a 32-signal composite quality model, placing it at rank #2,232 of 2,879 stocks — the bottom half of the AI-ranked universe. KIDS scores in the top quartile across revenue growth (82.7). Areas of concern include profitability (16.4) and free cash flow (16.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ORTHOPEDIATRICS CORP reports quarterly revenue of $59.4M, net income of $-10.7M, an operating margin of -14.0%. Top institutional holders of KIDS by reported 13-F value include BROWN ADVISORY, MILLENNIUM MANAGEMENT, BlackRock,, based on the most recent SEC filings. KIDS trades on the Nasdaq exchange and files with the SEC under CIK 1425450. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KIDS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ORTHOPEDIATRICS CORP directly from SEC EDGAR. ORTHOPEDIATRICS CORP's 13F Pro composite quality score has ranged between 8 and 74 since 2021, currently 33.4 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about ORTHOPEDIATRICS CORP

Quirks, history, and lore behind KIDS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Indiana, the orthopedic implant capital of the world.
2
The Numbers
Annual revenue in the range of $200–250 million — a niche player, but the dominant specialist in its corner of the orthopedic market.
3
The History
Founded in the early 2000s, it saw a gaping hole in orthopedics: most implants and surgical systems were designed for adult bodies, full stop.
4
The Secret
Its entire product portfolio is engineered specifically for growing skeletons — smaller anatomy, different bone density, different surgical needs than grown-ups.
5
The Lore
It works closely with pediatric orthopedic surgeons worldwide and has built a catalogue covering everything from scoliosis correction to limb deformity repair — for patients who can't yet drive themselves to the hospital.
6
The Giveaway
Its ticker is literally KIDS — because when you are the only publicly traded company focused exclusively on pediatric orthopedic implants, you earn that one.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$59.4M

Net Income

Q1 2026

$-10.7M

Free Cash Flow

Q1 2026

$-5.0M

Operating Margin

Q1 2026

-14.0%

D/E Ratio

Q1 2026

0.32

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+15.4% YoY

$236.3MFY 2025

FY20 $71.1MFY22 $122.3MFY24 $204.7MFY25 $236.3M

Net Income

-4.8% YoY

$-39.6MFY 2025

FY20 $-32.9MFY22 $1.3MFY24 $-37.8MFY25 $-39.6M

Operating Income

-12.1% YoY

$-39.2MFY 2025

FY20 $-26.8MFY22 $-25.4MFY24 $-35.0MFY25 $-39.2M

EPS (Diluted)

-3.0% YoY

$-1.69FY 2025

FY20 $-1.82FY22 $0.06FY24 $-1.64FY25 $-1.69

Total Assets

+7.5% YoY

$508.6MFY 2025

FY20 $320.4MFY22 $427.7MFY24 $473.2MFY25 $508.6M

Total Debt

+37.6% YoY

$107.9MFY 2025

FY20 $1.3MFY22 $1.1MFY24 $78.4MFY25 $107.9M

Op. Cash Flow

+82.1% YoY

$-4.9MFY 2025

FY20 $-18.5MFY22 $-21.8MFY24 $-27.0MFY25 $-4.9M

Metric	FY 2025	FY 2024	FY 2022	FY 2020	FY 2019	FY 2018
Revenue	$236.3M +15.4%	$204.7M +67.4%	$122.3M +72.0%	$71.1M -2.0%	$72.6M +26.0%	$57.6M
Net Income	$-39.6M -4.8%	$-37.8M -3106.5%	$1.3M +103.8%	$-32.9M -139.9%	$-13.7M -14.2%	$-12.0M
Operating Income	$-39.2M -12.1%	$-35.0M -37.8%	$-25.4M +5.1%	$-26.8M -194.8%	$-9.1M +5.0%	$-9.6M
EPS (Diluted)	$-1.69 -3.0%	$-1.64 -2833.3%	$0.06 +103.3%	$-1.82 -93.6%	$-0.94	—
Total Assets	$508.6M +7.5%	$473.2M +10.6%	$427.7M +33.5%	$320.4M +75.9%	$182.2M +62.5%	$112.1M
Total Debt	$107.9M +37.6%	$78.4M +7357.7%	$1.1M -19.5%	$1.3M -95.0%	$26.2M +23.1%	$21.3M
Operating Cash Flow	$-4.9M +82.1%	$-27.0M -24.3%	$-21.8M -17.5%	$-18.5M -4.3%	$-17.8M -14.0%	$-15.6M

AI Insight: KIDS Financial Trends

Revenue grew 13% year-over-year in Q1 2026 to $59M, but persistent operating losses and rising debt from $11M to $109M signal deteriorating fundamentals.

• Revenue increased from $52M in Q1 2025 to $59M in Q1 2026, representing 13% year-over-year growth.

• Operating losses persisted across all quarters, with operating income ranging from -$14M to -$6M throughout the period.

• Total debt surged from $11M in Q2 2024 to $109M in Q1 2026, nearly a 10x increase.

• Equity declined from $371M in Q2 2024 to $339M in Q1 2026, eroding shareholder value.

⚠ Operating cash flow turned positive to $10M in Q4 2025 but reversed to -$3M in Q1 2026.

⚠ Revenue volatility with sequential decline from $62M in Q4 2025 to $59M in Q1 2026.

AI Insight: KIDS Ratio Trends

OrthoPediatrics remains deeply unprofitable with operating margins deteriorating from -10.7% in Q2 2024 to -15.0% TTM despite modest sequential improvement in recent quarters.

• Operating margin improved sequentially from -20.9% in Q1 2025 to -14.0% in Q1 2026, though still worse than -10.7% in Q2 2024.

• ROIC remained deeply negative at -7.4% in Q1 2026, showing gradual improvement from -10.3% trough in Q1 2025.

• Debt-to-equity ratio increased significantly from 0.03 in Q2 2024 to 0.32 in Q1 2026.

⚠ All profitability metrics remain deeply negative across operating margin, net margin, ROE, ROA, and ROIC through Q1 2026.

⚠ Net profit margin volatility ranging from -11.4% to -30.5% over the past two years indicates unstable earnings quality.

Get alerted when KIDS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ORTHOPEDIATRICS CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KIDS

BROWN ADVISORY INC
$24.1M1,518,018 sh
MILLENNIUM MANAGEMENT LLC
$19.6M1,236,899 sh
BlackRock, Inc.
$18.6M1,174,046 sh
MORGAN STANLEY
$18.1M1,141,118 sh
BRAIDWELL LP
$17.5M1,100,370 sh
Granahan Investment Management, LLC
$14.2M896,741 sh
WELLINGTON MANAGEMENT GROUP LLP
$14.1M887,444 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.4M718,176 sh
Soleus Capital Management, L.P.
$9.8M615,447 sh
DIMENSIONAL FUND ADVISORS LP
$8.7M546,626 sh

Fund	Value	Shares
BROWN ADVISORY INC	$24.1M	1,518,018
MILLENNIUM MANAGEMENT LLC	$19.6M	1,236,899
BlackRock, Inc.	$18.6M	1,174,046
MORGAN STANLEY	$18.1M	1,141,118
BRAIDWELL LP	$17.5M	1,100,370
Granahan Investment Management, LLC	$14.2M	896,741
WELLINGTON MANAGEMENT GROUP LLP	$14.1M	887,444
VANGUARD CAPITAL MANAGEMENT LLC	$11.4M	718,176
Soleus Capital Management, L.P.	$9.8M	615,447
DIMENSIONAL FUND ADVISORS LP	$8.7M	546,626

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KIDS on your watchlist

Track score changes the day ORTHOPEDIATRICS CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KIDS a good stock to buy?

13F Pro's AI-powered analysis of ORTHOPEDIATRICS CORP (KIDS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KIDS are available on the KIDS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KIDS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KIDS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ORTHOPEDIATRICS CORP's investment landscape.